A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis

Table 2

Summary data on associations between ERCC1 polymorphisms and ORR, OS, and PFS of platinum-based chemotherapy in NSCLC.

	Study (cases)	Total	Study (cases)	Asian	Study (cases)	Caucasian
ERCC1 C118T
ORR
CT + TT versus CC	23 (3272)	0.82 [0.71, 0.96]	14 (2361)	0.80 [0.67, 0.94]	9 (911)	0.93 [0.66, 1.30]
		= 48.9%,		= 61.9%,		= 5.6%,
CT versus CC	16 (2023)	0.73 [0.61, 0.89]	9 (1499)	0.69 [0.55, 0.85]	7 (524)	0.93 [0.62, 1.38]
		= 9%,		= 0%,		= 16%,
TT versus CC	16 (1314)	0.63 [0.47, 0.85]	9 (985)	0.64 [0.44, 0.93]	7 (329)	0.63 [0.39, 1.01]
		= 19%,		= 20%,		= 30%,
OS
CT + TT versus CC	16 (2734)	1.25 [1.05, 1.50]	8 (1949)	1.24 [1.01, 1.53]	8 (785)	1.27 [0.88, 1.85]
		= 69.2%,		= 79.2%,		= 53.4%,
CT versus CC	5 (1276)	1.09 [0.86, 1.38]	5 (1276)	1.09 [0.86, 1.38]	0
		= 50%,		= 50%,
TT versus CC	5 (1276)	1.49 [1.18, 1.88]	5 (1276)	1.49 [1.18, 1.88]	0
		= 48%,		= 48%,
PFS
CT + TT versus CC	9 (943)	1.11 [0.84, 1.47]	3 (367)	1.15 [0.86, 1.54]	6 (576)	1.06 [0.64, 1.75]
		= 61.2%,		= 50.4%,		= 69.7%,
CT versus CC	1 (137)	1.47 [0.91, 2.36]	1 (137)	1.47 [0.91, 2.36]	0
TT versus CC	1 (137)	1.86 [1.13, 3.07]	1 (137)	1.86 [1.13, 3.07]	0
ERCC1C8092A
ORR
CA + AA versus CC	11 (1607)	0.87 [0.71, 1.07]	8 (1279)	0.76 [0.60, 0.96]	3 (328)	1.51 [0.95, 2.39]
		= 56.1%,		= 56.1%,		= 0%,
CA versus CC	6 (793)	0.71 [0.53, 0.96]	6 (793)	0.71 [0.53, 0.96]	0
		= 57%,		= 57%,
AA versus CC	6 (529)	0.42 [0.26, 0.70]	6 (529)	0.42 [0.26, 0.70]	0
		= 0%,		= 0%,
OS
CA + AA versus CC	5 (824)	1.18 [0.77, 1.79]	4 (705)	1.37 [1.06, 1.75]	1 (119)	0.50 [0.33, 0.84]
		= 77.6%,		= 26.4%,
CA versus CC	4 (569)	1.38 [1.03, 1.86]	4 (569)	1.38 [1.03, 1.86]	0
		= 0%,		= 0%,
AA versus CC	4 (569)	2.03 [1.19, 3.47]	4 (569)	2.03 [1.19, 3.47]	0
		= 54%,		= 54%,
PFS
CA + AA versus CC	1 (90)	1.08 [0.72, 1.63]	1 (90)	1.08 [0.72, 1.63]